Patent 7517910 was granted and assigned to Takeda Pharmaceutical Company on April, 2009 by the United States Patent and Trademark Office.
The present invention aims at provision of a novel compound having a GPR40 receptor function modulating action, which is useful as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes and the like. The compound represented by the formula: